res_code stringlengths 6 13 | treatment_phase stringclasses 432
values | authority_method stringclasses 3
values | treatment_of_code float64 4.08k 16.5k ⌀ | restriction_number float64 4.08k 16.5k ⌀ | li_html_text stringlengths 82 10.6k ⌀ | schedule_html_text stringlengths 41 12.3k | note_indicator stringclasses 2
values | caution_indicator stringclasses 2
values | complex_authority_rqrd_ind stringclasses 2
values | assessment_type_code stringclasses 2
values | criteria_relationship stringclasses 1
value | variation_rule_applied stringclasses 2
values | first_listing_date stringdate 1991-08-01 00:00:00 2025-05-01 00:00:00 | schedule_code int64 3.67k 3.67k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9642_4295_R | null | RESTRICTED | 4,295 | 9,642 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Phenylketonuria</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Phenylketonuria</p> <p align="justify">This formulation is suitable for patients aged 3 and older.</p> | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9652_9705_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 9,705 | 9,652 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be t... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9653_9745_R | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 9,745 | 9,653 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biolo... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biolo... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9667_9668_R | Subsequent continuing treatment | STREAMLINED | 9,668 | 9,667 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9671_9751_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 9,751 | 9,671 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9688_9688_R | null | STREAMLINED | 9,688 | 9,688 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Anaemia associated with intrinsic renal disease</p><br/><p>Patient must require transfusion; AND</p> <p>Patient must have a haemoglobin level of less than 100 g per L; AND</p> <p>Patient must have intrinsic renal disease, as assessed by a nephrolog... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Anaemia associated with intrinsic renal disease</p><br/><p>Patient must require transfusion; AND</p> <p>Patient must have a haemoglobin level of less than 100 g per L; AND</p> <p>Patient must have intrinsic renal disease, as assessed by a nephrolog... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9691_9691_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,691 | 9,691 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of renal allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND</p> <p>The treatment must be under the ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of renal allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of renal allograft re... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9692_9692_R | Management | STREAMLINED | 9,692 | 9,692 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Prophylaxis of renal allograft rejection</p><br/><p>Management</p><br/><p>The treatment must be under the supervision and direction of a transplant unit.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Prophylaxis of renal allograft rejection</p><br/><p>Management</p><br/><p>The treatment must be under the supervision and direction of a transplant unit.</p> <p>Management includes initiation, sta... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9693_9693_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,693 | 9,693 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of cardiac allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of cardiac allograft rejection; AND</p> <p>The treatment must be under ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of cardiac allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of cardiac allograf... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9694_9694_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,694 | 9,694 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Nephrotic syndrome</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must have failed prior treatment with steroids and cytostatic drugs; or</p> <p>Patient must be intolerant to treatment with steroids and c... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Nephrotic syndrome</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must have failed prior treatment with steroids and cytostatic drugs; or</p> <p>Patient... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9695_9695_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,695 | 9,695 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe atopic dermatitis</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Must be treated by a dermatologist; or</p> <p>Must be treated by a clinical immunologist; AND</p> <p>The condition must be ineffective to ot... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Severe atopic dermatitis</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Must be treated by a dermatologist; or</p> <p>Must be treated by a clinical immunologist... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9696_9696_R | null | STREAMLINED | 9,696 | 9,696 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Disorders of erythropoiesis</p><br/><p>The condition must be associated with treatment-related chronic iron overload.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Disorders of erythropoiesis</p><br/><p>The condition must be associated with treatment-related chronic iron overload.</p> | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9697_9697_R | null | STREAMLINED | 9,697 | 9,697 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of rejection in patients following organ or tissue transplantation</p><br/><p>The treatment must be under the supervision and direction of a transplant unit; AND</p> <p>The treatment must include initiation, stabilisation, and review of ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of rejection in patients following organ or tissue transplantation</p><br/><p>The treatment must be under the supervision and direction of a transplant unit; AND</p> <p>The treatment mu... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9709_9656_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 9,656 | 9,709 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consu... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consu... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9720_9669_R | Balance of supply for paediatric patient | AUTHORITY_REQUIRED | 9,669 | 9,720 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Balance of supply for paediatric patient</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterolo... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Balance of supply for paediatric patient</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterolo... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9725_9754_R | Balance of supply | AUTHORITY_REQUIRED | 9,754 | 9,725 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or<... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or<... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9732_9732_R | Subsequent continuing treatment | STREAMLINED | 9,732 | 9,732 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9742_9742_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,742 | 9,742 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe active rheumatoid arthritis</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexa... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Severe active rheumatoid arthritis</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>The condition must have been ineffective to prior treatment with classical slo... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9746_9655_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 9,655 | 9,746 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9747_9657_R | Continuing treatment | AUTHORITY_REQUIRED | 9,657 | 9,747 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9750_9719_R | Subsequent continuing treatment | AUTHORITY_REQUIRED | 9,719 | 9,750 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9757_9783_R | First continuing treatment | AUTHORITY_REQUIRED | 9,783 | 9,757 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9762_9762_R | Initiation and stabilisation | STREAMLINED | 9,762 | 9,762 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphosphataemia</p><br/><p>Initiation and stabilisation</p><br/><p>The condition must not be adequately controlled by calcium; AND</p> <p>Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; or</p> <... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphosphataemia</p><br/><p>Initiation and stabilisation</p><br/><p>The condition must not be adequately controlled by calcium; AND</p> <p>Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; or</p> <... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9764_9764_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,764 | 9,764 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of transplant rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must have had an organ or tissue transplantation; AND</p> <p>The treatment must be under the supervision and direction of ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of transplant rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must have had an organ or tissue transplantation; AND</p> <p>The treat... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9769_9770_R | Continuing treatment | AUTHORITY_REQUIRED | 9,770 | 9,769 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; ... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9772_9710_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 9,710 | 9,772 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9775_9775_R | Subsequent continuing treatment | STREAMLINED | 9,775 | 9,775 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9785_N | null | null | null | null | null | <p align="justify">Pharmaceutical benefits that have the form esomeprazole tablet 40 mg and pharmaceutical benefits that have the form esomeprazole capsule 40 mg are equivalent for the purposes of substitution.</p> | Y | N | N | null | null | N | 2015-07-01 | 3,671 |
9786_9677_R | Subsequent continuing treatment | AUTHORITY_REQUIRED | 9,677 | 9,786 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must have demonstrated an adequa... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must have demonstrated an adequa... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9797_9711_R | Balance of supply | AUTHORITY_REQUIRED | 9,711 | 9,797 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be tr... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be tr... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9802_9803_R | Change or Recommencement of treatment after a break in therapy of less than 5 years (Initial 2) | AUTHORITY_REQUIRED | 9,803 | 9,802 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Change or Recommencement of treatment after a break in therapy of less than 5 years (Initial 2)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a con... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Change or Recommencement of treatment after a break in therapy of less than 5 years (Initial 2)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a con... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9804_9787_R | Subsequent continuing treatment | STREAMLINED | 9,787 | 9,804 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9809_9809_R | Management | STREAMLINED | 9,809 | 9,809 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>WHO Class III, IV or V lupus nephritis</p><br/><p>Management</p><br/><p>The condition must be proven by biopsy; AND</p> <p>Must be treated by a nephrologist or in consultation with a nephrologist.</p> <p align="justify">The name of the consulting n... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>WHO Class III, IV or V lupus nephritis</p><br/><p>Management</p><br/><p>The condition must be proven by biopsy; AND</p> <p>Must be treated by a nephrologist or in consultation with a nephrologist.... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9813_9822_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 9,822 | 9,813 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastro... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastro... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9816_9721_R | First continuing treatment | AUTHORITY_REQUIRED | 9,721 | 9,816 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)];... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)];... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9820_9651_R | Continuing treatment - balance of supply | AUTHORITY_REQUIRED | 9,651 | 9,820 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroent... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroent... | N | N | Y | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9821_9823_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 9,823 | 9,821 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p... | N | N | Y | FULL | ALL | N | 2019-11-01 | 3,671 |
9828_9828_R | null | STREAMLINED | 9,828 | 9,828 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Bronchospasm</p><br/><p>Patient must be unable to achieve co-ordinated use of a metered dose inhaler containing a short-acting beta-2 agonist; or</p> <p>Patient must have developed a clinically important product-related adverse event during treatme... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Bronchospasm</p><br/><p>Patient must be unable to achieve co-ordinated use of a metered dose inhaler containing a short-acting beta-2 agonist; or</p> <p>Patient must have developed a clinically important product-related adverse event during treatme... | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9831_9831_R | null | STREAMLINED | 9,831 | 9,831 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of transplant rejection</p><br/><p>The treatment must be used by organ or tissue transplant recipients.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of transplant rejection</p><br/><p>The treatment must be used by organ or tissue transplant recipients.</p> | N | N | N | IMMEDIATE | ALL | N | 2019-11-01 | 3,671 |
9908_9987_R | Initial treatment | STREAMLINED | 9,987 | 9,908 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Patient must be antiretroviral treatment naive; AND</p> <p>Patient must not have suspected resistance to either antiretroviral component.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Patient must be antiretroviral treatment naive; AND</p> <p>Patient must not have suspected resistance to either antiretroviral component.</p> | N | N | N | IMMEDIATE | ALL | N | 2019-12-01 | 3,671 |
9914_9914_R | Management (initiation, stabilisation and review of therapy) | STREAMLINED | 9,914 | 9,914 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Management of renal allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND</p> <p>The treatment must be under the ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Careful monitoring of patients is mandatory.</p> <p>Management of renal allograft rejection</p><br/><p>Management (initiation, stabilisation and review of therapy)</p><br/><p>Patient must be receiving this drug for prophylaxis of renal allograft re... | N | N | N | IMMEDIATE | ALL | N | 2019-12-01 | 3,671 |
9915_N | null | null | null | null | null | <p align="justify">Unlike Symbicort Turbuhaler 200/6, Symbicort Rapihaler 200/6 is not recommended nor PBS-subsidised for use as 'maintenance and reliever' therapy as the approved Product Information does not specify such use.</p> | Y | N | N | null | null | N | 2014-01-01 | 3,671 |
9927_9334_R | null | STREAMLINED | 9,334 | 9,927 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe spasticity of the lower limb following an acute event</p><br/><p>Must be treated by a neurologist; or</p> <p>Must be treated by an orthopaedic surgeon; or</p> <p>Must be treated by a rehabilitation specialist; or</p> <p>Must be t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe spasticity of the lower limb following an acute event</p><br/><p>Must be treated by a neurologist; or</p> <p>Must be treated by an orthopaedic surgeon; or</p> <p>Must be treated by a rehabilitation specialist; or</p> <p>Must be t... | N | N | N | IMMEDIATE | ALL | N | 2019-12-01 | 3,671 |
9956_9981_R | Initial treatment | STREAMLINED | 9,981 | 9,956 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Patient must be antiretroviral treatment naive.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Patient must be antiretroviral treatment naive.</p> | N | N | N | IMMEDIATE | ALL | N | 2019-12-01 | 3,671 |
9977_N | null | null | null | null | null | <p align="justify">Pharmaceutical benefits that have the forms doxycycline tablet 100 mg (as hyclate (hydrochloride)), doxycycline tablet 100 mg (as monohydrate) and doxycycline modified release capsule 100 mg (as hyclate (hydrochloride)) are equivalent for the purposes of substitution.</p> | Y | N | N | null | null | N | 2014-04-01 | 3,671 |
9991_9993_R | Initial treatment | STREAMLINED | 9,993 | 9,991 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Urea cycle disorders</p><br/><p>Initial treatment</p><br/><p>Patient must have elevated ammonia levels that are not controlled with diet alone and other adjunct care alone.</p> <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2</h1><p... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Urea cycle disorders</p><br/><p>Initial treatment</p><br/><p>Patient must have elevated ammonia levels that are not controlled with diet alone and other adjunct care alone.</p> <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2</h1><p... | N | N | N | IMMEDIATE | ALL | Y | 2019-12-01 | 3,671 |
9992_9919_R | Continuing treatment | STREAMLINED | 9,919 | 9,992 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Urea cycle disorders</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition.</p> <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2</h1><p align="jus... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Urea cycle disorders</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition.</p> <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2</h1><p align="jus... | N | N | N | IMMEDIATE | ALL | Y | 2019-12-01 | 3,671 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.